Interchangeability, immunogenicity and biosimilars

被引：84

作者：

Ebbers, Hans C. ^{[1
]}

Crow, Stacy A. ^{[2
]}

Vulto, Arnold G. ^{[2
]}

Schellekens, Huub ^{[3
,4
]}

机构：

[1] Univ Utrecht, UIPS, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands

[2] Erasmus Univ, Dept Hosp Pharm, Med Ctr, Rotterdam, Netherlands

[3] Univ Utrecht, Copernicus Inst, Dept Innovat & Environm Studies, Utrecht, Netherlands

[4] Univ Utrecht, Dept Pharmaceut, UIPS, Utrecht, Netherlands

来源：

NATURE BIOTECHNOLOGY | 2012年 / 30卷 / 12期

关键词：

GENERIC SUBSTITUTION; EPOETIN-ALPHA; RENAL ANEMIA; SAFETY; NEED;

D O I：

10.1038/nbt.2438

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

For authorized biosimilars to achieve full acceptance in the marketplace, it is crucial that they are considered to be therapeutically equivalent and interchangeable with the brand reference product.

引用

页码：1186 / 1190

页数：5

共 34 条

[1]

[Anonymous], 2004, Off. J. Eur. Union

[2]

Quality of Original and Biosimilar Epoetin Products [J].

Brinks, Vera ;

Hawe, Andrea ;

Basmeleh, Abdul H. H. ;

Joachin-Rodriguez, Liliana ;

Haselberg, Rob ;

Somsen, Govert W. ;

Jiskoot, Wim ;

Schellekens, Huub .

PHARMACEUTICAL RESEARCH, 2011, 28 (02) :386-393

[3]

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].

Casadevall, N ;

Nataf, J ;

Viron, B ;

Kolta, A ;

Kiladjian, J ;

Martin-Dupont, P ;

Michaud, P ;

Papo, T ;

Ugo, V ;

Teyssandier, I ;

Varet, B ;

Mayeux, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475

[4]

Covic, Adrian ;

Cannata-Andia, Jorge ;

Cancarini, Giovanni ;

Coppo, Rosanna ;

Frazao, Joao M. ;

Goldsmith, David ;

Ronco, Pierre ;

Spasovski, Goce B. ;

Stenvinkel, Peter ;

Utas, Cengiz ;

Wiecek, Andrzej ;

Zoccali, Carmine ;

London, Gerard .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (12) :3731-U32

[5]

Biosimilars: controversies as illustrated by rhGH [J].

Declerck, Paul J. ;

Darendeliler, Feyza ;

Goth, Miklos ;

Kolouskova, Stanislava ;

Micle, Ioana ;

Noordam, Cees ;

Peterkova, Valentina ;

Volevodz, Natalia N. ;

Zapletalova, Jirina ;

Ranke, Michael B. .

CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (05) :1219-1229

[6]

Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study [J].

Dellanna, F. ;

Winkler, R. E. ;

Bozkurt, F. ;

Schettler, V. ;

Graf, S. ;

Bockreiss, N. ;

Fliser, D. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (01) :64-72

[7]

Generic and therapeutic substitutions in the UK: are they a good thing? [J].

Duerden, Martin G. ;

Hughes, Dyfrig A. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (03) :335-341

[8]

The safety of switching between therapeutic proteins [J].

Ebbers, Hans C. ;

Muenzberg, Michael ;

Schellekens, Huub .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (11) :1473-1485

[9]

European Medicines Agency, SCI GUID DOC BIOS ME

[10]

European Medicines Agency, 2007, GUID IMM ASS BIOT DE

← 1 2 3 4 →